Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Auranofin modulates human neutrophil superoxide production and protein phosphorylation

Summary

The effect of auranofin (AF) was examined on human neutrophil superoxide production and protein phosphorylation stimulated by phorbol esters. Low concentrations of auranofin (≤0.5 μM) enhanced while higher concentrations (0.5–10 μM) inhibited superoxide release stimulated by a suboptimal concentration (0.005 μM) of phorbol myristate acetate (PMA). The enhancing but not the inhibitory effect of AF was lost if a maximal stimulating dose (0.05 μM) of PMA was used. In contrast AF had a biphasic effect on protein phosphorylation regardless of the stimulating concentration of PMA. Comparison of the dose-response curves for these effects of AF suggest that although changes in protein phosphorylation may be partly responsible for altered activity of the NADPH oxidase responsible for superoxide production, it is unlikely that they are mediated by a direct effect of AF on protein kinase C. Also, measurement of 3H-PDBu-binding to neutrophils showed that these actions of AF could not be attributed to altered binding of phorbol esters to their cellular receptor (protein kinase C).

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Blodgett RC (1983) Auranofin: experience to date. Am J Med 75 (6A):86–89

  2. 2.

    Crooke ST, Snyder RM, Butt TR, Ecker D, Allaudeen HS, Monia B, Mirabelli CK (1986) Cellular and molecular pharmacology of auranofin and related gold complexes. Biochem Pharmacol 35:3423–3431

  3. 3.

    Bluhm GB (1982) The mechanism of action of conventional chrysotherapy. J Rheumatol 9 (suppl 8):10–17

  4. 4.

    Salmeron G, Lipsky PE (1982) Modulation of human immune responsiveness in vitro by auranofin. J Rheumatol 9 (suppl 8):25–31

  5. 5.

    Hurst NP (1987) Molecular basis of activation and regulation of the phagocyte respiratory burst. Ann Rheum Dis 46:265–272

  6. 6.

    Weening RS, Wever R, Roos D (1975) Quantitative aspects of the production of superoxide radicals by phagocytosing human granulocytes. J Lab Clin Med 85:245–252

  7. 7.

    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

  8. 8.

    Zalewski PD, Forbes IJ, Valente L, Hurst NP (1979) Auranofin increases the affinity of phorbol dibutyrate receptors in CLL cells (B-cells). J Immunol 138:3005–3009

  9. 9.

    James DW, Ludvigssen NW, Cleland LG, Milazzo SC (1982) The influence of cigarette smoking on blood distribution of gold during chrysotherapy. J Rheumatol 9:532–535

  10. 10.

    Froscio M, Murray AW, Hurst NP (1989) Inhibition of protein kinase C activity by the antirheumatic drug auranofin. Biochem Pharmacol (in press)

  11. 11.

    Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661–665

  12. 12.

    Hafstrom I, Seligmann BE, Friedman MM, Gallin JI (1984) Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor mediated stimuli. J Immunol 132:2007–2014

  13. 13.

    Sung C-P, Mirabelli CK, Badger AM (1984) Effect of gold compounds on phorbol myristate acetate activated superoxide production by mouse peritoneal macrophages. J Rheumatol 11:153–157

  14. 14.

    Parente JE, Davis P, Wong K (1987) Gold compounds alter distribution of protein kinase C activity in human neutrophils. Inflammation 11:381–388

  15. 15.

    Hafstrom I, Uder A-M, Palmblad J (1983) Modulation of neutrophil functions by auranofin. Scand J Rheumatol 12:97–105

  16. 16.

    Snyder RM, Mirabelli CK, Clark MA, Ziegler JT, Crooke ST (1987) Effect of auranofin and other gold complexes on the activity of phospholipase C. Mol Pharmacol 32:437–442

  17. 17.

    Hurst NP, Bessac B, Bell AL, Nuki G (1986) Studies of the effect of penicillamine and sodium aurothiomalate therapy on superoxide production by monocytes from patients with rheumatoid arthritis — evidence for in vivo stimulation of monocytes. Ann Rheum Dis 45:37–43

  18. 18.

    Walz DT, DiMartino MJ, Griswold DE (1982) Comparative pharmacology and biological effects of different gold compounds. J Rheumatol 9 (suppl 8):54–60

  19. 19.

    Lorber A, Jackson WH, Simon TM (1982) Effects of chrysotherapy on cell mediated immune response. J Rheumatol 9 (suppl 8):37–45

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hurst, N.P., Gorjatschko, L., Betts, W.H. et al. Auranofin modulates human neutrophil superoxide production and protein phosphorylation. Rheumatol Int 8, 245–250 (1989). https://doi.org/10.1007/BF00270979

Download citation

Key words

  • Auranofin
  • Superoxide
  • Phagocytes
  • Protein phosphorylation
  • Protein kinase C